New drug combo targets Hard-to-Treat ovarian and endometrial cancers
NCT ID NCT05950464
First seen Jun 25, 2026 · Last updated Jul 10, 2026 · Updated 8 times
Summary
This early-phase trial is testing the safety and best dose of two drugs, M1774 and ZEN-3694, given together to patients with recurrent ovarian or endometrial cancer. The drugs work by blocking enzymes that cancer cells need to grow. The study aims to find a dose that is safe and potentially effective, especially in tumors with a specific genetic change (ARID1A loss).
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- M1774 (ATR inhibitor) and ZEN-3694 (BET inhibitor)
- What this could lead to
- If successful, this could lead to a new treatment option for patients with recurrent ovarian or endometrial cancer that has stopped responding to standard therapies.
- What could go wrong
- This is an early phase 1 trial with only 65 participants, so safety and dosing are still being determined. The combination may cause side effects or not work as hoped.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Augusta University Medical Center
SUSPENDEDAugusta, Georgia, 30912, United States
-
Case Western Reserve University
ACTIVE_NOT_RECRUITINGCleveland, Ohio, 44106, United States
-
Cleveland Clinic Foundation
RECRUITINGCleveland, Ohio, 44195, United States
Contact Email: •••••@•••••
-
Medical College of Wisconsin
RECRUITINGMilwaukee, Wisconsin, 53226, United States
-
NRG Oncology
RECRUITINGPhiladelphia, Pennsylvania, 19103, United States
-
Ohio State University Comprehensive Cancer Center
RECRUITINGColumbus, Ohio, 43210, United States
-
Thomas Jefferson University Hospital
RECRUITINGPhiladelphia, Pennsylvania, 19107, United States
Contact Email: •••••@•••••
-
University of Chicago Comprehensive Cancer Center
RECRUITINGChicago, Illinois, 60637, United States
Contact Email: •••••@•••••
-
University of Iowa/Holden Comprehensive Cancer Center
RECRUITINGIowa City, Iowa, 52242, United States
-
University of New Mexico Cancer Center
RECRUITINGAlbuquerque, New Mexico, 87106, United States
-
University of Oklahoma Health Sciences Center
RECRUITINGOklahoma City, Oklahoma, 73104, United States
-
University of Pennsylvania/Abramson Cancer Center
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact Email: •••••@•••••
-
Wayne State University/Karmanos Cancer Institute
SUSPENDEDDetroit, Michigan, 48201, United States
-
Women and Infants Hospital
RECRUITINGProvidence, Rhode Island, 02905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill target Hard-to-Treat ovarian cancers?
- Digital therapy aims to tame the fear that haunts cancer survivors
- Can a natural compound boost chemotherapy against endometrial cancer?
- Can a new nucleotide analogue boost cancer treatment?
- A remote diet and exercise program aims to help rural cancer survivors shed pounds and lower recurrence risk
- Can a smart drug missile take down a tough ovarian cancer?